|
NL269416A
(enExample)
|
1960-09-21 |
|
|
|
|
GB8819826D0
(en)
|
1988-08-20 |
1988-09-21 |
Kabivitrum Ab |
Glycosylated igf-1
|
|
US5679771A
(en)
|
1990-02-13 |
1997-10-21 |
Gropep Pty. Ltd. |
Method for treating intestinal diseases
|
|
ES2178635T3
(es)
|
1990-11-09 |
2003-01-01 |
Stephen D Gillies |
Inmunoconjugados de citoquinas.
|
|
US5632986A
(en)
|
1991-05-09 |
1997-05-27 |
The University Of Washington |
Phospholipid-targeted thrombolytic agents
|
|
US5444045A
(en)
*
|
1992-09-17 |
1995-08-22 |
Gropep, Pty. Ltd. |
Method of administering IGF-1, IGF-2, and analogs thereof to birds
|
|
WO1995019791A1
(en)
*
|
1994-01-24 |
1995-07-27 |
Neorx Corporation |
Radiolabeled annexins
|
|
EP0756494A1
(en)
|
1994-05-24 |
1997-02-05 |
Amgen Boulder Inc. |
Modified insulin-like growth factors
|
|
US5780052A
(en)
|
1995-04-24 |
1998-07-14 |
Northeastern University |
Compositions and methods useful for inhibiting cell death and for delivering an agent into a cell
|
|
JPH11508608A
(ja)
|
1996-04-17 |
1999-07-27 |
ニューロクライン バイオサイエンシーズ，インコーポレイテッド |
インスリン様成長因子結合タンパク質のリガンドインヒビターおよびそれらの使用方法
|
|
US6121416A
(en)
|
1997-04-04 |
2000-09-19 |
Genentech, Inc. |
Insulin-like growth factor agonist molecules
|
|
EP1098665B9
(en)
|
1998-07-13 |
2003-08-13 |
The Board Of Regents, The University Of Texas System |
Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids
|
|
US6387663B1
(en)
|
1998-07-31 |
2002-05-14 |
University Of Southern California |
Targeting pharmaceutical agents to injured tissues
|
|
AUPP785098A0
(en)
|
1998-12-21 |
1999-01-21 |
Victor Chang Cardiac Research Institute, The |
Treatment of heart disease
|
|
DE60042550D1
(de)
|
1999-01-06 |
2009-08-27 |
Genentech Inc |
Mutierte varianten des insulin-ähnlichen wachstumsfaktor i (igf-i)
|
|
US7087411B2
(en)
|
1999-06-08 |
2006-08-08 |
Regeneron Pharmaceuticals, Inc. |
Fusion protein capable of binding VEGF
|
|
CA2378925C
(en)
|
1999-07-21 |
2010-04-06 |
University Of Southern California |
Matrix-targeted fusion polypeptides for tissue regeneration and wound healing
|
|
JP2001251104A
(ja)
|
2000-03-03 |
2001-09-14 |
Murata Mfg Co Ltd |
非可逆回路素子及び通信機装置
|
|
DE60141759D1
(de)
|
2000-08-29 |
2010-05-20 |
Aurogen Inc |
Methode zur behandlung des zentralnervensystems durch applikation von strukturanaloga von igf
|
|
EP2796468A2
(en)
|
2001-01-05 |
2014-10-29 |
Pfizer Inc |
Antibodies to insulin-like growth factor I receptor
|
|
US7635680B2
(en)
|
2001-02-21 |
2009-12-22 |
Alavita Pharmaceuticals, Inc. |
Attenuation of reperfusion injury
|
|
AU2002256423B2
(en)
|
2001-04-30 |
2008-07-24 |
Zystor Therapeutics, Inc. |
Subcellular targeting of therapeutic proteins
|
|
US7049286B2
(en)
|
2001-08-30 |
2006-05-23 |
Diatos, S.A. |
Insulin conjugates and methods of use thereof
|
|
AU2008200706B2
(en)
|
2001-10-16 |
2010-05-27 |
Biomarin Pharmaceutical Inc. |
Methods and compositions for targeting underglycosylated proteins across the blood brain barrier
|
|
US20030072761A1
(en)
|
2001-10-16 |
2003-04-17 |
Lebowitz Jonathan |
Methods and compositions for targeting proteins across the blood brain barrier
|
|
EP1622645B1
(en)
|
2002-04-23 |
2013-10-23 |
Roger Williams Hospital |
Compositions and methods for stem cell delivery
|
|
JP4444821B2
(ja)
*
|
2002-06-06 |
2010-03-31 |
ツェ・チェイン・ウン |
遺伝子組み換えによる新しい抗凝血性蛋白質
|
|
US9321832B2
(en)
|
2002-06-28 |
2016-04-26 |
Domantis Limited |
Ligand
|
|
US20040213738A1
(en)
|
2003-03-31 |
2004-10-28 |
Susan Croll-Kalish |
CIRL3-Like proteins, nucleic acids, and methods of modulating CIRL3-L-mediated activity
|
|
WO2005033134A2
(en)
|
2003-09-30 |
2005-04-14 |
Regeneron Pharmaceuticals, Inc. |
Secreted protein therapeutics and uses thereof
|
|
JP2007531513A
(ja)
*
|
2003-11-13 |
2007-11-08 |
ハンミ ファーム．インダストリー カンパニー リミテッド |
薬物のキャリアとして有用なＩｇＧＦｃ断片およびその製造方法
|
|
JP2007536254A
(ja)
|
2004-05-05 |
2007-12-13 |
メリマック ファーマシューティカルズ インコーポレーティッド |
生物活性を調節するための二重特異性結合剤
|
|
WO2006004910A2
(en)
|
2004-06-28 |
2006-01-12 |
Transtarget Inc. |
Improved bispecific antibodies
|
|
US7511016B2
(en)
|
2004-07-07 |
2009-03-31 |
Mosamedix B.V. |
Annexins, derivatives thereof, and annexin-cys variants, as well as therapeutic and diagnostic uses thereof
|
|
AU2005277094A1
(en)
|
2004-08-20 |
2006-03-02 |
Regenerx Biopharmaceuticals, Inc. |
Method of treating, preventing, inhibiting or reducing damage to cardiac tissue
|
|
US7531318B2
(en)
|
2004-08-20 |
2009-05-12 |
Board Of Regents, The University Of Texas System |
Screening of agents for activity against ischemic myocardial insults
|
|
JP2008517917A
(ja)
*
|
2004-10-21 |
2008-05-29 |
アイジーエフ オンコロジー エルエルシー |
癌を治療するための毒素および放射性核種結合ｉｇｆ−１受容体リガンド
|
|
ATE517120T1
(de)
|
2005-01-07 |
2011-08-15 |
Regeneron Pharma |
Igf-1 fusion polypeptide und deren therapeutische verwendung
|
|
US20090098046A1
(en)
|
2005-01-14 |
2009-04-16 |
Michael Becker |
Combination Cancer Therapy with Anti-PSMA Antibodies
|
|
SG158919A1
(en)
|
2005-01-24 |
2010-02-26 |
Univ Texas |
Constructs binding to phosphatidylserine and their use in disease treatment
|
|
EP1853309A4
(en)
|
2005-02-23 |
2008-10-22 |
Merrimack Pharmaceuticals Inc |
BISPECIFIC BINDER FOR MODULATING BIOLOGICAL ACTIVITY
|
|
US7521211B2
(en)
|
2005-04-05 |
2009-04-21 |
Regeneron Pharmaceuticals, Inc |
IGF-1 and IGF-2 chimeric polypeptides and therapeutic uses thereof
|
|
AU2006249327A1
(en)
|
2005-05-27 |
2006-11-30 |
Five Prime Therapeutics, Inc. |
Methods of and compositions for stimulation of glucose uptake into muscle cells and treatment of diseases
|
|
AU2006280312A1
(en)
|
2005-08-12 |
2007-02-22 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
|
US7855279B2
(en)
|
2005-09-27 |
2010-12-21 |
Amunix Operating, Inc. |
Unstructured recombinant polymers and uses thereof
|
|
WO2007044887A2
(en)
|
2005-10-11 |
2007-04-19 |
Transtarget, Inc. |
Method for producing a population of homogenous tetravalent bispecific antibodies
|
|
EP1960790B1
(en)
|
2005-12-12 |
2016-12-28 |
MosaMedix B.V. |
Annexin derivatives suitable for pretargeting in therapy and diagnosis
|
|
US7776816B2
(en)
|
2006-01-20 |
2010-08-17 |
Board Of Regents, The University Of Texas System |
Preserving hypoxic tissue
|
|
AU2007212147A1
(en)
|
2006-02-03 |
2007-08-16 |
Medimmune, Llc |
Protein formulations
|
|
GEP20135917B
(en)
|
2006-03-17 |
2013-09-10 |
Biogen Idec Inc |
Stabilized polypeptide compositions
|
|
CL2007001614A1
(es)
|
2006-06-09 |
2008-08-08 |
Novartis Ag |
Polipeptido que comprende una proteina del precursor del factor de crecimiento tipo insulina, igf-1 humana, en la cual la escision del peptido e mediante una proteasa se reduce a traves de la modificacion de la proteina del precursor; y su uso para t
|
|
US9187517B2
(en)
|
2006-11-13 |
2015-11-17 |
The Brigham And Women's Hospital, Inc. |
Methods of promoting cardiac repair using growth factors fused to heparin binding sequences
|
|
US8003761B2
(en)
|
2007-01-23 |
2011-08-23 |
Hoffmann-La Roche Inc. |
Cancerous disease modifying antibodies
|
|
SE0700218L
(sv)
|
2007-01-23 |
2008-02-26 |
Teknikbolaget K Samuelsson Ab |
Sprutmunstycksanordning för brandsläckningssystem
|
|
US11535673B2
(en)
|
2007-04-05 |
2022-12-27 |
President and Fellows of Harvard CoHege |
Chimeric activators: quantitatively designed protein therapeutics and uses thereof
|
|
US8889140B2
(en)
|
2007-05-31 |
2014-11-18 |
Transtarget, Inc. |
Compositions and methods for tissue repair
|
|
US20110045007A1
(en)
|
2007-05-31 |
2011-02-24 |
Genmab A/S |
Fusion or linked proteins with extended half life
|
|
HRP20110368T1
(hr)
|
2007-06-21 |
2011-06-30 |
Technische Universitt Mnchen |
Biološki aktivni proteini s povećanom stabilnošću in vivo i/ili in vitro
|
|
WO2009030720A2
(en)
|
2007-09-06 |
2009-03-12 |
Novozymes Biopharma Dk A/S |
Process for producing a recombinant protein
|
|
EA022201B1
(ru)
|
2008-04-11 |
2015-11-30 |
Мерримак Фармасьютикалз, Инк. |
Агент, способный связываться с опухолевой клеткой, содержащий линкер на основе hsa, и его применение
|
|
JP5677972B2
(ja)
|
2008-11-18 |
2015-02-25 |
メリマック ファーマシューティカルズ インコーポレーティッド |
ヒト血清アルブミンリンカーおよびそのコンジュゲート
|
|
WO2010087976A2
(en)
*
|
2009-01-31 |
2010-08-05 |
Igf Oncology, Llc |
Anti-cancer protein-platinum conjugates
|
|
BR112012001363A2
(pt)
|
2009-07-22 |
2016-11-08 |
Ipsen Pharma Sas |
análogo de igf-1, composição farmacêutica,e, método para tratar condições ou doenças mediadas pela ligação do receptor de igf-1
|
|
WO2011011071A2
(en)
|
2009-07-22 |
2011-01-27 |
Ipsen Pharma S.A.S. |
Analogues of insulin-like growth factor-1 (igf-1)
|
|
CA2777242A1
(en)
|
2009-10-14 |
2011-04-21 |
Merrimack Pharmaceuticals, Inc. |
Bispecific binding agents targeting igf-1r and erbb3 signalling and uses thereof
|
|
BR112012009450A2
(pt)
|
2009-10-30 |
2017-05-23 |
Novozymes Biopharma Dk As |
variantes de albumina
|
|
JP6200806B2
(ja)
|
2010-05-21 |
2017-09-20 |
メリマック ファーマシューティカルズ インコーポレーティッド |
二重特異的融合タンパク質
|
|
EP2649177B1
(en)
|
2010-12-08 |
2018-09-05 |
ViaCyte, Inc. |
Agents and methods for inhibiting human pluripotent stem cell growth
|
|
EP2780364A2
(en)
|
2011-11-18 |
2014-09-24 |
Eleven Biotherapeutics, Inc. |
Proteins with improved half-life and other properties
|
|
CN104114575B
(zh)
|
2011-12-15 |
2019-04-09 |
爱德迪安（北京）生物技术有限公司 |
具有降血糖作用的化合物、组合物及其用途
|
|
CN108383902A
(zh)
|
2012-09-26 |
2018-08-10 |
印第安纳大学研究及科技有限公司 |
胰岛素类似物二聚体
|
|
US20160122411A1
(en)
|
2013-03-29 |
2016-05-05 |
Merrimack Pharmaceuticals, Inc. |
Cartilage-binding fusion proteins
|
|
EP3094339B1
(en)
|
2014-01-12 |
2019-12-11 |
IGF Oncology, LLC |
Fusion proteins containing insulin-like growth factor-1 and epidermal growth factor and variants thereof
|
|
CN115960249A
(zh)
|
2015-10-02 |
2023-04-14 |
银溪制药股份有限公司 |
用于组织修复的双特异性治疗性蛋白质
|